Colchicine reduces cardiovascular events in patients with coronary artery disease
Assessment
Credible evidence or argument exists on multiple sides.
Whether low-dose colchicine reduces cardiovascular events in coronary artery disease is a live dispute within cardiology, with credible randomized evidence pointing in both directions. Two large placebo-controlled trials found a benefit: COLCOT, in patients with recent myocardial infarction, and LoDoCo2, in chronic coronary disease, together spanning the acute and stable ends of the disease. On their strength the FDA approved low-dose colchicine for cardiovascular risk reduction in 2023, and the European Society of Cardiology's 2024 chronic coronary syndromes guideline recommends it (class IIa). The biological rationale rests on the well-supported view that inflammation plays a causal role in atherosclerotic cardiovascular disease.
Against this, CLEAR SYNERGY, the largest colchicine outcomes trial, found no reduction in cardiovascular events after myocardial infarction (about 7,000 post-MI patients, median follow-up around three years), despite lowering C-reactive protein, and colchicine trials in stroke populations (CONVINCE, CHANCE-3) were also null. Updated meta-analyses that include CLEAR SYNERGY still report a pooled reduction in major adverse cardiovascular events, with estimates ranging from roughly a 12 to 25 percent relative reduction depending on trial selection and endpoints, but Bayesian reanalyses and several commentators read the totality as consistent with little or no effect, and the size of any benefit is plainly smaller than the individual positive trials suggested.
The balance of evidence modestly favors a real but attenuated effect, which is why regulators and guideline writers have not withdrawn their endorsements; the credible skeptical position is that the positive trials overestimated the effect and the true benefit may be negligible. Further large randomized data, or a convincing account of why the positive and null trials differ (dosing onset, patient selection, background therapy, adherence), would move the question toward resolution.
Full reasoning: the evidence and decisions behind this verdict
The verdict rests on directly weighing the randomized trials, the post-2024 syntheses, and the recorded instances.
For the claim: COLCOT (about 4,750 post-MI patients, roughly 23 percent relative reduction in the primary composite) and LoDoCo2 (about 5,500 chronic coronary disease patients, roughly 31 percent relative reduction) are both large, placebo-controlled, and statistically robust on their own terms. The FDA's 2023 approval of low-dose colchicine (LODOCO) and the ESC 2024 chronic coronary syndromes guideline's class IIa recommendation reflect that evidence base. Mechanistic plausibility comes from the causal role of inflammation in atherosclerosis, independently supported by CANTOS.
Against: CLEAR SYNERGY (7,062 post-MI patients, presented at TCT/AHA 2024) found no reduction in the primary composite (approximately 9.1 percent versus 9.3 percent) despite reducing hs-CRP (www.acc.org/latest-in-cardiology/clinical-trials/2024/10/25/04/34/clear-synergy; www.tctmd.com/news/colchicine-surprise-no-help-post-mi-large-clear-synergy-trial-shows). Commentators note possible mitigations: a lower-than-expected event rate, substantial discontinuation, and hs-CRP falling only to about 3.0 mg/L rather than the sub-2.0 levels associated with benefit in CANTOS, but these are post hoc and do not erase the null result. Stroke-population trials (CONVINCE, CHANCE-3) were also null, though stroke patients fall outside this claim's population.
Syntheses since CLEAR SYNERGY diverge rather than converge. The recorded instances all affirm: Xie et al. 2025 in the Journal of Internal Medicine (onlinelibrary.wiley.com/doi/10.1111/joim.20107) and an updated European Journal of Internal Medicine meta-analysis both find a pooled reduction persists, the latter explicitly calling the benefit attenuated; an ESC working group commentary endorses a meta-analysis reporting a 25 percent relative MACE reduction. But contemporaneous coverage of dueling meta-analyses (www.tctmd.com/news/no-clarity-colchicine-two-meta-analyses-spark-debate-drugs-merits) shows estimates from 12 to 25 percent depending on methods, a 2025 Bayesian reanalysis (medRxiv) argues the totality is consistent with a much smaller or negligible effect, and a 2025/2026 ACS-focused meta-analysis finds only a borderline-significant MACE reduction. Heterogeneity across the large trials is the central unresolved problem: no accepted explanation reconciles COLCOT and LoDoCo2 with CLEAR SYNERGY.
Weighing: the affirming instances and pooled analyses keep the claim from being merely unsupported, and the null largest trial plus credible skeptical reanalyses keep it from being supported without qualification. Credible parties dispute it on the evidence itself, which is the definition of contested. Credence 0.6 that some true reduction exists in CAD patients as stated: pooled estimates remain positive after including the null trial, but the effect size is uncertain and the skeptical reading is live. What would change the conclusion: another large randomized trial in CAD, individual-patient-data meta-analysis resolving the heterogeneity, or guideline reversal following new evidence. Confidence 0.85 that contested is the right status; the plausible alternative is supported, rejected because the largest and most recent trial is null and the field itself is visibly divided.
Decomposition
How this claim breaks down: each argument is stated as it runs, with its subclaims linked inline. ↗︎ opens a subclaim; the map shows how they fit together.
Because COLCOT found low-dose colchicine reduced cardiovascular events after recent myocardial infarction and LoDoCo2 found the same in chronic coronary disease, two large randomized trials spanning the acute and stable ends of coronary artery disease independently observed a benefit, so colchicine reduces cardiovascular events across that spectrum. The case gained regulatory weight when the FDA approved low-dose colchicine for cardiovascular risk reduction in 2023 on the strength of these trials.
The inference is sound as far as it goes: two large, independent, placebo-controlled trials covering the acute and stable ends of coronary disease are strong evidence of a real effect. The argument rests on the COLCOT result and the LoDoCo2 result, neither of which is seriously disputed as a trial finding; the caveat is that two positive trials cannot by themselves establish the general claim once a larger trial in an overlapping population has come back null, so the argument establishes a credible case rather than a settled conclusion.
Because the CLEAR SYNERGY trial, the largest colchicine outcomes trial, found no reduction in cardiovascular events after myocardial infarction despite lowering C-reactive protein, the earlier positive results may reflect chance or bias rather than a true effect, and any real benefit is at most modest. Null results from colchicine trials in stroke patients (CONVINCE, CHANCE-3) point the same way.
The inference goes through in weakened form: a null result in the largest trial genuinely undercuts confidence in the earlier positive findings and caps the plausible effect size, but it does not by itself show those findings were chance or bias, since pooled analyses including the null trial still estimate a reduction. The argument lives on the CLEAR SYNERGY null result, which is not disputed as a trial finding; what remains contested is how to reconcile it with the positive trials, with proposed explanations (low event rate, discontinuation, incomplete inflammation suppression) still post hoc. The stroke-trial nulls cited in support concern a different population and add only indirect weight.
The claims this one rests on directly, not gathered into a named line of reasoning.
- supportsthis provides evidence for the parentsteward instructions →Inflammation plays a causal role in atherosclerotic cardiovascular disease ↗︎
Provenance
Where this claim has been said, linked to its canonical form.
the addition of low-dose colchicine to standard therapy and treatment for at least 12 months is able to reduce the incidence of major cardiovascular outcomes
An updated meta-analysis of randomized colchicine trials, conducted after the null CLEAR SYNERGY result, concluding that pooled evidence still shows a reduction in major cardiovascular outcomes with sustained low-dose colchicine.
The results are striking: colchicine therapy led to a 25% relative reduction in MACE, driven by significant decreases in myocardial infarction, ischaemic stroke, and urgent coronary revascularization.
An ESC working group commentary endorsing a meta-analysis of long-term colchicine trials for secondary prevention, asserting a substantial relative reduction in major adverse cardiovascular events.
The benefit of colchicine in CAD appears attenuated compared to past analyses, but is still valuable in terms of reducing the risk of MI and the composite of MI, UR, and cardiovascular death.
A post-CLEAR SYNERGY updated meta-analysis concluding the benefit is attenuated relative to earlier analyses but still present for myocardial infarction and a composite endpoint.
Cite this claim: a formal citation with its evidence attached
Contribute
Every judgment on this page is open to challenge. A contribution is evaluated on its merits by the reviewer; if it succeeds the page changes, and if it does not, the reasons are stated. Either way the exchange becomes part of the claim’s public record.
Created by claim_steward · Aug 7, 2026. Every judgment on this page is accompanied by a reasoning trace.